246: Vas Narasimhan on the future of pharma, plus Moderna’s promise & a biotech presidential bid The Readout Loud (STAT) · 16 Feb 2023 Source: https://soundcloud.com/readout-loud/246-vas-narasimhan-on-the-future-of-pharma-plus-modernas-promise-a-biotech-presidential-bid Transcript: https://podcasts.opennash.com/shows/the-readout-loud/246-vas-narasimhan-on-the-future-of-pharma-plus-modernas-promise-a-biotech-presi-b46ed1/ (via OpenNash Podcasts, machine-generated) Welcome to this week's episode of The Readout Loud, a weekly biotech podcast from STAT. I'm Meg Terrell. I'm Adam Feuerstein. And I'm Damian Garde. It's Thursday, February 16th, and here's what we're going to talk about this week. Vas Narasimhan, CEO of Novartis and the new chairman of Pharma, joins us to discuss the industry's struggles in Washington and whether the biotech industry is still overvalued. We'll also explain the latest news in the life sciences, including a vaccine promise from Moderna and the possible presidential run of a former biotech CEO. But first, a word from our sponsor. Attention healthcare innovators and biotech enthusiasts. Are you ready to explore the intersection of medicine, biology, and technology? Then mark your calendars for the STAT Breakthrough Summit this spring in San Francisco. This event brings together leaders across the industry to discuss how to unlock the full potential of this exciting new era in medicine. Speakers include Stephen Gillett, the CEO of Verily, and Jennifer Doudna, the co-inventor of CRISPR. These experts will share their insights on how technology and innovation are transforming healthcare for the benefit of patients. Plus, the summit will be led by STAT reporters, giving you access to the latest developments in the field and in-depth analysis of the industry. So join us this May 3rd and 4th at the STAT Breakthrough Summit, and be a part of the conversations delving into the incredible advancements happening in the field that are shaping the future of health care. Learn more and register today for a limited discounted ticket at statnews.com slash summit. So leading off this week with some interesting news from Moderna, which, of course, markets one of the approved COVID-19 vaccines in the United States, and which had said in the past, much like Pfizer, another marketer of such vaccines, that it would raise the price somewhat considerably of each dose of its COVID-19 vaccine once those vaccines stop being distributed for free by the government and move on into commercial insurance. Now, the news is Moderna said they are committed to ensuring that anyone in the United States who wants a booster dose of its vaccine can get it without paying any money out of pocket. And the details there basically are that they will institute one of the drug industry's familiar patient assistance programs such that people who are uninsured or underinsured can get their doses for free by, you know, Moderna moving money around so as to cover them. But what it didn't really make clear is how the company would ensure that the everybody else who's on commercial insurance would also pay $0 out of pocket. Meg, what did you make of the the announcement? Well, it kind of came out of nowhere. It just landed in my inbox. And then I realized, because another thing landed in my inbox from Senator Bernie Sanders's press office, touting that Moderna CEO Stefan Boncel had agreed to appear and testify in a hearing sort of hilariously titled, taxpayers paid billions for it. So why would Moderna consider quadrupling the price of the COVID vaccine. I think we're in the new era of Bernie Sanders helming the Senate Help Committee. And this is going to be very interesting to watch. So I wonder actually, if Stefan Bunzel is going to DC in person, this is a hearing that's happening on March 22, or if this is going to be virtual, because when these things happen virtually, it's much less uncomfortable for the CEOs, it seems like because they're not always on camera. But I do think it's interesting that Bancel accepted this invitation to testify. It clearly shows that he thinks they are in the right here and they're doing, you know, the right stuff and that he can stand up to the berating he's inevitably going to get from Bernie Sanders. You know, this was presented as sort of Moderna making an about face after pressure from Bernie Sanders. And I don't know what happened behind the scenes at Moderna, but it didn't necessarily seem that way to me. And it seems like a fairly standard thing for a company to do to A, have a patient assistance program for people who are uninsured or underinsured. From the insurance standpoint, you know, this is something that Pfizer CEO Albert Bourla has been out there on as well, actually saying that there are provisions in the Inflation Reduction Act that would take away any co-pays that insured people have, including for COVID vaccines. I don't know the ins and outs of that. And because it doesn't seem like this is something that people are accepting concretely. I do need to understand that better. But perhaps that is something that would explain why people with insurance would not have a copay. I was confused by this because from what I understand it, and I think anyone who has private insurance, even probably through their employer, I mean, a lot of vaccines, including like probably the flu vaccine is probably what we're most familiar with, are offered for free. It's part of your insurance coverage and you don't pay co-pay, you don't pay for the vaccine. So my impression was that COVID vaccines would be covered similarly. Is that not correct? Anyone have an idea about that? I think it's probably similar. And I don't think that there's some massive change. It's not like Moderna saying, okay, no, we're not quadrupling the price anymore. Like they're probably still increasing the list price of these vaccines and insurance will cover them. So there's still a higher cost to the system. But, you know, the actual cost to people who want to get the vaccines, they are saying should still be nothing. So I guess we'll see how this plays out. And on March 22nd, we will see Stefan Bunzel and Bernie Sanders head to head. I will. It'll be particularly fun to to listen to Stefan Banzel speak to Bernie Sanders, just given their differing accents. Let's keep it, you know, put it that way. Yeah, two mellifluous speakers of the English language. I would say, if in fact, Moderna's statement is related to Bancel's coming appearance at this hearing, then I was wrong. We spoke on this podcast before about what a Sanders-led Senate help committee might mean and whether it would lead to anything meaningful. and I said certainly no legislation and probably nothing meaningful at all, but maybe some entertaining committee hearings. But if, you know, this hearing is happening and if Moderna made this pledge, which maybe they were going to make otherwise, it does suggest that, I mean, this being the first salvo, I think, of Sanders running the help committee and maybe not the, this probably won't be the last pharmaceutical CEO who is called before them for something conceivably theatrical. So, you know, this could be an interesting, interesting period of time. OK, so we have a great interview to get to with Vas Narasimhan. So we want to leave lots of room for that. So we're going to do a lightning round of a few other important topics of biotech news this week, starting with, and do it quickly, Adam, Biogen earnings. Yeah, Biogen. You know, this was the first opportunity for investors to hear new CEO Chris Wiebacher speak on an earnings call. Obviously, he's spoken before. He was at the JP Morgan conference. But this was his first earnings call. No big surprises on the call. The company guided down earnings and revenue for the coming year, but that was expected. I think probably my biggest takeaway is that as someone who covers biotech, who covers Biogen pretty closely, my enemy is boring. I do not like the mundane. I do not like boring. I don't think Chris Vietbacher is going to be boring. I think he's been put in place at Biogen to shake things up, to take some risks. He will need the alignment with his board, which, as we know, has been particularly fractious. Although we did hear some news that Stelios Papadopoulos, the longtime chairman, is resigning from the war, stepping back from the board. And that's due to Biogen's mandatory age retirement policy. But, yeah, I think it'll be an exciting, you know, months, months and years ahead with Chris Wibacher running Biogen. The retirement of the godfather. He'll still be the godfather. I was going to say, you know, just when you think you're out, famously, they pull you back in. But we can move on. I see that as a lead to a future story that David will write about Stelios. Moving on, Meg, tell us about this advisory committee meeting pertaining to Narcan. Yeah. So, of course, Narcan is the brand name for the nasal spray version of naloxone, the opioid overdose antidote, this incredible drug that's been around since the 70s, which can literally wake somebody up from an opioid overdose. Right now, these are all prescription-based. So this was an advisory committee meeting to consider Emergent BioSolutions application to take Narcan over the counter. Everybody remembers Emergent BioSolutions. This is the company that famously during the pandemic was manufacturing the J &J vaccine and the AstraZeneca vaccine and mixed up some of the ingredients. So, you know, Narcan is going to face generic competition fairly soon. And so some analysts I was talking with said, you know, they are doing this essentially because they're about to face cheap generic copies. But also from a public health standpoint, this is incredibly important. Increasing access to Narcan could help save lives. And the committee ended up voting 19 to 0 in favor of turning this over the counter. Now, the question is going to be where does emergent biosolutions price this? Does it actually make it accessible for people? Some of the reporting I've been doing suggests it's still going to be fairly pricey for people to be paying for this, you know, even though it's not prescription. But I guess we're going to have to see emergent biosolutions as saying it's premature to discuss pricing, unsurprisingly. But it does sound like the FDA is likely to approve this to move over the counter. And then, you know, we'll have to see what happens to the other versions of naloxone, which are injectable? Will they also try to move over the counter? And what will happen when generic copies come to the market? But most importantly, hopefully this will increase access to this drug. All right. So next up, Damien, tell us about J &J's new chief scientific officer. Yeah. So early one morning, we learned that John Reed, who had spent about five years running the research and development operation at Sanofi, would be leaving the company. And then about eight hours after that did we learn that J &J had hired him to do basically the same job, which I think is notable in that when you zoom out, that means he's replacing Matai Mamon, who we've spoken about, was briefly a candidate for the Biogen CEO position, who left J &J's top research position. Similarly, over at Novartis, Jay Bradner left the analogous position there. And I guess maybe this is looking for a trend where one doesn't exist, but there does seem to be a little bit of musical chairs in the highest ranks of science in the pharmaceutical industry. Maybe there's nothing to read through. Each of those people had multi-year tenures and people tend to move around in jobs like that. But that in keeping with or happening at the same time as the CEO transition at Bayer, which I don't think we spoke about on this podcast, there's just change afoot at the highest levels of some of the largest drug makers, specifically in Europe. And I don't know, maybe there's an explanation for that, but I haven't connected the dots to the point where I have a thesis to present. You're still in this stage where you have a clip, you know, a big board on the wall and red string trying to connect. I've got a lot of red string. Heads of R &D. I haven't slept in weeks. Yeah. Speaking of change, a biotech entrepreneur and investor is considering a presidential run, apparently. Adam, tell us about Vivek Ramaswamy. Yeah. So there was a story in Politico this week that basically said that Vivek Ramaswamy, as you said, Meg, he's the biotech entrepreneur, former hedge fund manager. Probably people know him most as the, I guess, the former CEO of Roy Vant. Now he's chairman of Roy Vant. That he is testing the waters. I guess that's the political term, right? Testing the waters of a presidential run. I guess largely on this sort of anti-woke platform that he has championed mostly through a book that he's written and many, many, many appearances on Fox TV cable, the cable network. Yeah, it's interesting. Well, first of all, politics is hilarious because, yeah, it is described as testing the waters. But reading the Politico story about this testing of the waters, testing the waters means he's hired like 15 people. I'm sure, you know. And gotten a story published in Politico. That's probably part of this. Whatever. That's neither here nor there. I think what's interesting is, yeah, to your point, Vivek's star turn on Tucker Carlson and elsewhere is based on this notion that wealth managers, the black rocks of the world, by focusing on what is described as ESG and, you know, racial and ethnic diversity and gender diversity and spending your money is the way it goes. if you are a person with a retirement account that's managed by one of these massive fund managers, to advance a political agenda that is, according to Vivek, kind of at odds with mainstream America. And it's kind of like a niche point. It's hard to imagine going to a diner in Iowa and really connecting with some random person on the notion of woke fund managers, you know, or that like fidelity has been taken over by a leftist cabal within Wall Street. It feels like a little bit of an absurdity. But obviously, if Vivek has gotten this far in this process, then he has consulted with the various powers that be and knowers of how things work within the Republican Party such that he feels like and they feel like he has a shot. I'm interested to see how this plays out. I'm interested to watch the evolution of his message as he takes it to a larger kind of like GOP populace. And I'm reticent to write it off in part because, you know, it's 2023. In 2015, I would have said, as did many people, that Donald Trump had very little chance of winning the Republican primary, let alone the presidency. And of course, both of those things eventually happen. I'm not likening Vivek to Trump necessarily, but I just don't feel confident enough to make any kind of prediction as to how this is going to go. I think that is a point that was also made by activist investor Bill Ackman, who threw his support behind Vivek on Twitter this week. I'll also note Maxim Jacobs on Twitter suggested, like Nikki Haley, I think he is running for a cabinet position. Which cabinet position do you think Vivek would be suited for? Or at least might be put into? Well, I thought Bill Ackman was throwing his support behind Vivek because maybe Bill wants to be Treasury Secretary or Fed Chair. But maybe that actually - Everybody's just running for a cabinet position. Right. Maybe that's actually Vivek's. Maybe he wants to be Fed Chair. So, you know, we'll see. I mean, my feeling getting back to Damien's point is like, I feel like Vivek has tried to kind of wrap this sort of anti-wokeness and kind of an intellectual rapper, you know, kind of make it sound more academic than sort of the red meat topic issue that it really is. And Ron DeSantis from Florida has kind of grabbed hold of that, too. So, like, are there going to be these two competing anti-woke presidential candidates out there? I also kind of look ahead and say, like, if he does sort of become a credible candidate, you know, you can kind of see opponents in opposition research out there that is starting to will examine Vivek's record as a hedge fund manager. And, you know, invariably someone will find some cancer drug stock that he shorted when he when he was at his hedge fund. And, you know, that will become some, you know, 30 second TV ad. last week there was a change at the top of pharma or the pharmaceutical research and manufacturers of america which is of course the trade group representing the drug industry novartis ceo Vas Narasimhan became the chair of the board of directors vas has been ceo of novartis since 2018. And he recently revealed to me at the JPMorgan Healthcare Conference that he is a regular listener of The Readout Loud. So, of course, we wanted to invite him on. Vaz, welcome to the podcast. Hey, Meg, great to be here. Great to be here with you, Adam and Damian. Huge fan of the podcast, so really excited to speak with you all. So let's start with the role you've just taken for pharma, a group that spends about $30 million a year in lobbying. What are the issues that you are most focused on there? Three main issues, Adam. First, you know, when you think about the IRA, trying to get adjustments to the IRA that we think would be more pro-innovation and really ensuring the right medicines get to the Medicare patient population. In particular, we believe that the nine years of protection before price controls take hold in the small molecule space is simply too short to really allow us to do the indication expansions, focus on rare diseases, and also to ensure oncology and cardiovascular medicines really reach the patients that need it. So that's one big focus. Second is PBM reform. And that's been, I think, a long topic for the industry. But the hope is we can get reforms in place with the goal in mind that we want patients to pay at the pharmacy counter or at the hospital the net price that the insurers pay. And that's net of all of the rebates that we provide. And if that were to happen, patients would find their drugs more affordable, starting with the first dollar, and of course, also would impact their co-pays as well. And as you know, in many drug classes, that rebate can be as much as 70 % of the list price of the drug. And the third priority is continuing to reform the 340B program, where, you know, the intention of that program is to allow patients from low-income communities or communities that don't have access to great healthcare to access better healthcare. We fully support that. But this is a program that's expanded far, we believe, beyond its remit and needs to get better clarity on what are the eligible institutions, the eligible patient populations, so that it actually serves its intended purpose. So those would be the three top priorities for the pharma this year. So the legislation you're referring to is, of course, the Inflation Reduction Act, which passed and carried these provisions that affect the drug industry, as you described. the passage of that bill and its signing into law was perceived, I think, as a pretty massive defeat and a failure for pharma in terms of advocating for itself. Those are my words and not yours. But I'm curious, you know, with that in such recent past, moving forward, I don't know, is there a process of evaluating what went wrong from the pharma side such that this happened in the first place when setting in motion the stuff that you just described? I think it's an important point, Damian. We've had that discussion at the board level to really see what are the learnings we can take away. And I think that the biggest learning is we need to be more proactive as an industry and offering solutions to clearly the challenges that constituents are putting forward to policymakers. And I think if we can get sharper at that, do better at that, hopefully we can get better policy in place. I think it's important to note with the Inflation Reduction Act, there's some really good things that happen. I think that the out-of-pocket cap for patients in Medicare and the smoothing that's happened is going to allow patients to afford their medicines in an effective way. And I think that was a real success of the legislation. But I think when you look at some of the damaging provisions, like the price setting after nine years in small molecules, that will have a big impact on what is really about 60% of the drugs this industry generates and many of those drugs targeting the elderly population. So I think we've got to get sharper at offering good solutions in the future. Is there anything more specific you can say about what pharma plans to do about the provisions in the IRA that the industry opposes? I mean, maybe even more specifically, do you plan to sue to stop some of those provisions? Well, I think there's going to be a couple of steps in this whole process. First, you know, Medicare and I think many of the companies have had the opportunity, and Medicare has been very open to feedback from pharma and the industry on the various provisions. It's going to put forward draft guidance on how they're planning to implement, how they select drugs, how they then think about to negotiate the price-setting provision across nine different parameters, and how they'll actually implement the rebates. And I think once those come out, we'll have the opportunity to comment. And certainly, I think if the industry perceives that these aren't sensible, we'll have to look at what actions we can take. And I think it's still early days to really determine that. I think longer term, we'd want to look at legislative fixes to the provisions around nine years for small molecules. I think that'll take time, though. I mean, realistically, given where Congress is right now, we have to see if there's really any vehicle or any opportunity to shift that. If you think about the impact that's going to have, if you are going to develop a new oncology medicine, which you have to do multiple life cycle managements, and you know this well, if you think about rare diseases where we stack multiple indications over time, if you think about small molecule cardiovascular drugs where it takes time for these drugs to get taken up, I mean, nine years is a very short window to make significant investments to actually get those returns back. So I think it will harm innovation in that part of the ecosystem over time. So you mentioned that nine-year provision really affecting sort of drug development decisions. Maybe sort of segueing into our conversation about Novartis as well, are you guys making decisions about not developing drugs in certain ways for certain indications because of that provision? Yes. I mean, I think it's having an impact on how we look at new, I would say, new development programs. Of course, in-flight development programs, we continue forward. But I think when you think about, let's say, let's take a case study, if you have an oncology medicine where you know that it's predominantly for the elderly and you're going to have to step through a late-line therapy to an earlier line, to the adjuvant, to fully capture the opportunity and make the investment make sense. And then you look at only a nine-year runway to do that. That's actually very challenging. And then, of course, there's the debate, could you hold back, wait? But then I think you get into an ethical conundrum of can you develop a medicine and then not make it available as each indications data set comes through. So that makes you, and when you have multiple opportunities of where you invest your resources to develop new drugs, then of course you have to make those trade-offs. So it is having, I think, a tangible impact on the decisions we're taking. So you just crossed your fifth anniversary as CEO. When you started, I think the narrative around Novartis was facing some patent expirations and had big decisions to make about its eye care. and generics business. Now, cue to the present, and you've been describing Novartis as, quote, the next pure play innovation medicines company. What does that mean exactly? And what has changed about Novartis since when you took over the company as CEO? Yeah, thanks. When you look at this company, it's a 250-year-old company. It started in the dye-making industry, went to chemicals, and then slowly evolved into a healthcare conglomerate when Novartis in its current form was created in 1996. And we had 1.8 divisions, including areas like animal health, Gerber baby food. Of course, as you mentioned, Alcon, Sandoz, consumer health, a vaccines division, which I was heavily involved in. I think what we see today is given how fast science is evolving, technology is evolving, you have to be focused in one sector of healthcare and then even focus within therapeutic areas if you want to be competitive. So over the last five years, we've done about $100 billion of transactions to exit consumer health, eye care devices, our planned spin of Sandoz, also some of the investments we had, such as our stake in Roche, and really say, look, we're going to be pure play, innovative medicines. What we believe is differentiating about our approach is we focus on certain therapeutic areas where there isn't a lot of investment, like cardiovascular disease, but also therapeutic areas like oncology, immunology, neuroscience, where there's a lot of investment. And then focus on these new technology platforms where we're one of the leaders in gene therapies, siRNAs, radioligand therapies, cell therapies, areas where we think medicine is going to head over the next 15 years. And if we can focus and do that well, that will be the way we create value to society and our shareholders. But that's a very different view. And I think many companies in our sector now are heading down that line of moving from a really broad conglomerate to focusing more and more on innovative medicines. So we'll get to, I think, each of those subtopics and technologies as well. But I wanted to ask you, I mean, speaking of the divestitures, that's led to you all carrying quite a bit of cash on your balance sheet, which has led to you facing similar repetitive, maybe at this point, agonizing questions about just how you'll spend it. But I did clock that I think is on a recent earnings call that you mentioned you're looking at things that you might purchase in biotech, But keeping it at a limit of about $5 billion per transaction, I was curious, how come? And what does the field of targets look like at that price? And how did that strategy come about? Well, first, I feel remiss if I didn't acknowledge the fact that I listened to your podcast, I think, a couple of months back. And you had a great analyst from Oppenheimer on who really went through the whole biotech sector. And one of the things that's striking when I get this question is also, we don't talk enough about what happened in this sector over the last decade when there was so much money available and so many companies formed, was that actually a good thing? And many of these companies probably don't have as rigorous enough science to have gotten as far as they have in the development path. So now fast forward to today, when we look at, okay, how do you do M &A? We have a lot of firepower on our balance sheet. One of the challenges is finding really high quality science to acquire, because in the end, just because assets are underpriced or lower priced, That doesn't necessarily mean we need to collect them. And we need things that have credibility that can ultimately get to market and have a high impact on patients. And that's been a challenge. Right now, where we see the biggest opportunity to find value is in this kind of sub $5 billion, I would say, mid-stage development space. At least that's our hypothesis. Where you could maybe unlock some opportunities where we have expertise, we have scale, and we can find a way to make big drugs out of that. But it is a challenge, I would say. And I do wonder if the kind of full reckoning and Damon, you and Adam cover biotech intensely. Has the full reckoning happened yet of kind of the cleanup of the sector? And that's something that certainly I'm watching. And maybe you're helping with that, with some of the some of the deals. Well, maybe. I mean, I think, look, we've also found a lot of opportunities kind of at the low end of this thing. I mean, a lot of these companies, as you know, are trading under their under their cash value, which makes them very eager to unload assets. And then you can find really good assets there. I mean, in places that don't even make the press releases and don't even make the kind of news feeds. But you can find interesting assets because those companies now need to to kind of clean up their portfolios. So it'll be interesting to see, I think, how the next couple of years evolve. Is, you know, inheriting that question, I wonder, is it because interesting assets that you do find either they're highly valued or maybe overpriced, or is it just difficult to find interesting assets like that the science or the companies that are out there sort of starting up that they're wanting in some way, they're, you know, they're lacking in some way, and you guys are kind of passing on them? I think there's three categories. I mean, there's companies that have very good assets or very good science, and the markets have very well valued them. And then if you want to play in that space, you have to pay significant premiums. And I mean, some companies are willing to do that. We're trying to take a financially disciplined approach about how we approach those kind of what I would characterize as very well analyzed, well valued companies. I think there are these companies that have solid emerging science, which you could take bets on. And certainly, I think that's where we're really looking for opportunities. And then there's a set of companies that say they've gotten pretty follow-on in development. And when we look more carefully at them, we don't see that the right steps have been taken, whether that's in technical development, clinical development, engagement with regulators. And then when we get closer, we have pause, right? And is it a good acquisition to make given that profile? I don't know why that's happened necessarily, but I have a hypothesis. It's just because you had a lot of capital available and able to advance very quickly, very far into development. So I think the analyst you're referring to is probably Jared Holtz. But I thought you were going to mention that we talked about Ronnie Gao, who you guys hired. Yeah, as your chief strategy and growth officer last year. And of course, we were really sad that he was leaving the analyst community because he really is kind of a different personality. So how is Ronnie doing at Novartis? And what is he doing and how is he helping with your strategy? So Ronnie's been a great asset. I mean, I think fully meaning the hopes I had that he would bring, I think, a very unvarnished and very content-rich perspective on our own assets, on our own pipeline, but also bringing in the external view of that kind of competitive analysis. Maybe you guys used to benefit from Ronnie's weekly report when he was at Bernstein on the sector. Now I get that report once a week, and it's very much focused on what's happened in the sector and how that's impacting Novartis medicines. And so he's having a great impact. I think he's settling in well. Of course, there's a transition into the corporate world. But I'm doing my best to protect him as best I can from not being able to – I want him to be able to say what he thinks and really feel like he can give us the unvarnished truth. So drilling down a little bit, you mentioned, you know, that Novartis is really among the sectors that you've really chosen to specialize in or sell in gene therapy. And it seems like, you know, even zooming out from Novartis, that the next couple of years are likely to be pivotal years in the business of gene therapy with multiple approvals and launches of medicines anticipated in sickle cell disease, hemophilia, where patients have other treatment options. And so it seems like it's kind of a proving ground for how this technology can really make a mark in those therapeutic areas. So I'm just curious for your thoughts on the challenges to date and the outlook when it comes to pricing and getting reimbursement and really securing patient access for some of these one-time medicines. Yeah, as you guys know, with Zolgensma, we had an important experience, probably a formative experience in the industry where we were able to launch a transformative medicine. And in that case, I think pretty remarkable efficacy in kids who are particularly kids who are under six months of age. It's been successful. It's a blockbuster medicine. We're reimbursed in 38 countries. We have in general, when newborn screening happens, the medicine has high uptake. And then what happened, at least I think in the sector and also in our own experiences, it became a lot harder to find a good match between a gene therapy, a disease, the right vector, the right construct. And so I think the science then had to catch up. I think it is catching up. And now I think, Damien, to your point, there's going to be the question of there are gene therapies that are addressing diseases that have no really good therapies. And if that's a severe enough disease and you have enough efficacy like the Zolgensma story, I think you can make a pretty successful medicine. I think when you have alternative treatments, the question is, particularly if you have to take in some instances, some of the therapies you mentioned, you have to do bone marrow conditioning. And these are pretty heavy if you're going to do ex vivo cell therapies. How many patients are ultimately going to want to do that versus chronic therapies they already have and how are payers going to view that? I think those are going to be important questions. And I think it's going to be also important to figure out from a payment model standpoint, Zolgensma alone didn't change the model to kind of what people had thought, which would be payments over time. Let's say a phased payment rather than paying the full amount in the first year. It wasn't big enough to really make payers want to shift. The question is when you have five, six, seven gene therapies, you probably do need a model change. And you're going to need not only a model change at the state level, at the insurer level, but also how best price is calculated. I mean, there are many things that have to fall into place in the United States to allow you to do pay over time or pay for performance. And I think those topics are going to come to a head. I don't know exactly how it's going to play out. I ultimately believe if you have a cell and gene therapy with transformative efficacy with Kimriah, with Zolgensma, with others in the space, you can get broad access. The question will be when you have kind of modest or solid but not transformative efficacy, you still have a one-time therapy, high price, how are pairs going to navigate that? It'll be interesting to see. Where do you see the outlook for, getting back to cell therapy, particularly CAR-T, I think one of the interesting dynamics in play has been the patient-specific therapies versus the off-the-shelf and sort of the development of off-the-shelf therapies. What's your thought on where the field is going? It seems like just sort of where I look at it from my perspective is that there was a lot of excitement about off-the-shelf cell therapies, but maybe it's waned a little bit. You know, there's been questions about durability. And it seems like particularly as the as the kind of the patient specific CAR T's have moved ahead into earlier lines of care that they've kind of, you know, they've sort of kind of got really settled into the market and are making or gaining ground. What's your thoughts on that? Yeah, I think on cell therapy, when you think about autologous cell therapy, the dynamics have been that all the companies are getting their cost of goods down and getting this much more efficient supply up. And I think we and others are working on what we call rapid CAR T's. We call ours T-charts, but others have them as well, which are trying to reduce COGS even further, increase capacity more. So that kind of eliminates, at least in our view, the need for allocarts, you know, off-the-shelf CAR T therapies. A lot of the value proposition goes away based on those technologies. So I think that's one dynamic you're seeing play out. I think the other ones are very important when you raise, Adam, as these therapies get earlier and earlier in the lines of care, it's harder to do comparative studies because you have to do a comparative study versus an established therapy in one of those lines of care. And so if you're a small biotech and you want to do a head-to-head versus one of the established CAR-T therapies, this is not at all straightforward to pull off. I think the other dynamic I think that's going to come, and already many companies are working on it, including us, is how CAR therapy, cell therapies are going to impact other severe conditions outside of oncology. There was a huge amount of effort to move from B cell tumors into solid tumors. Solid tumors are so heterogeneous, it's been hard to find, I think, reliable targets that have really generated good efficacy. But there's been some pretty impressive findings on patients who have severe immunological diseases where cell therapies seem to have an impact. And I expect many players now to shift to say, can you apply these technologies? It would be in severe patient populations to our earlier discussion because you need bone marrow conditioning. But in those patients who have no other alternative with severe immunological diseases, Could CART therapy be a solution? I think it's going to be an important trend to watch. Okay, we have kept you for a long time. So we're going to transition now into more of a rapid fire set of questions that might be slightly more fun than the ones we've posed to you so far. The first one, most exciting new technology that has the most potential to be transformative to medicine. What is it right now? Within Novartis, it's radioligand therapy. I mean, it's a little bit off maybe the general path. But the results we're seeing now in solid tumors with radioligin therapies are pretty extraordinary. I think in the longer term for cardiovascular disease and other, I think, siRNAs, and especially as we can direct siRNAs to tissues beyond the liver, I think long-acting therapies that patients only need every six months or one year are going to transform healthcare over time. Okay, which of these cities has better food? Cambridge, Massachusetts, or Basel, Switzerland? Oh, Cambridge, Massachusetts. To be a fair disclosure, I lived in Boston, I think, for eight or ten years, and we continue to have a home in the Boston area. So, yeah, and I lived in Cambridge as well for eight years. My kids were born while we lived in Cambridge, so I'm a Cambridge restaurant. What's your go-to Cambridge dining spot, where you like to go? Now, I don't know what the promotional impact will this be, but Oleana. I love Oleana. I think it's one of my favorites. Yeah, great. What about that's a great restaurant? What about a casual spot? Where does you and the family go when you just need to get a quick bite to eat out in Cambridge? Area four pizza. All right. Good choice. Also good for the biotech mingling right there next to all of the biotech companies. So, Vaj, you may have heard that biotech investor and entrepreneur Vivek Ramaswamy is reported to be considering a presidential run. Do you think that this industry provides good training to be president? Well, I know Vivek, and I think he's a brilliant person. So all hats off for him for his aspirations. I don't know if this industry provides training to be a president. Certainly being a CEO provides training on many dimensions I would have never imagined. And maybe some of those might be useful in politics. But yeah, that's probably all I can say on that, Adam. Well, with that, Voss, thank you so much for joining us. Thank you, guys. Really an honor to be here. Really appreciate it. I do love the podcast. I think it's really, really well done. I love when Helen comes on board. I think she's really, really good on the pandemic. As a vaccinologist by background, I love listening to her talk about pandemics. I mean, the one she did last week on avian influenza was really, really good. So, yeah, I think, guys, keep going. I mean, I think it's really good. That does it for another episode of The Readout Loud. Thank you to Teresa Gaffney for producing this week's episode. Our senior producers are Hyacinth Ambinato and Alyssa Ambrose. Our executive producer is Rick Burke. And our theme music is by Brian Joel. And we'd love to hear from you. Tell us what you like about this week's episode, what you didn't like, and whether you'd prefer Meg or Damien to go out on the campaign trail with Vivek. I am too old to do that. You can do all that by sending us an email at readoutloud at statnews.com. And if you like what we do, leave a review or a rating on Apple Podcasts or whichever platform you use to get your podcast. See you next week.